NCT02101138View on ClinicalTrials.gov

Study to Evaluate Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome

PHASE2UnknownINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 14, 2014

Primary Completion Date

December 30, 2016

Study Completion Date

October 23, 2019

Conditions
Hypereosinophilic Syndrome
Interventions
DRUG

Dexpramipexole

Dexpramipexole (KNS 760704) is a synthetic amino-benzothiazole developed for use in amyotrophic lateral sclerosis (ALS)

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

Sponsors

Collaborators (1)

Knopp Biosciences
All Listed Sponsors
collaborator

Knopp Biosciences

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH